<DOC>
	<DOCNO>NCT02971722</DOCNO>
	<brief_summary>JY09ï¼Œis recombinant glucagon-like peptide-1 ( GLP-1 ) receptor agonist , construct Exendin-4 human Immunoglobulin G2 ( IgG2 ) Fc fragment.Preclinical study show JY09 exhibit expect GLP-1-mediated pharmacological effect insulin secretion , glucose cover islet cell recovering , well good tolerance safety.JY09 approve China food drug administration ( CFDA ) enter clinical research stage ( Grant number 2016L04254 ) .This study design assess safety , tolerability , pharmacokinetics , pharmacodynamics potential immunogenicity JY09 healthy Chinese volunteer .</brief_summary>
	<brief_title>Study JY09 Chinese Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy subject . Male 's mass equal great 50 kg , female 's mass equal great 45 kg , body mass index ( BMI ) 18 28 kilogram per square meter ( kg/m^2 ) , inclusive . The subject sign inform consent form voluntarily . The subject agree use instrument contraception time first dose 6 month last dose investigational drug , avoid pregnancy make mate . Participants able keep good communication investigator comply requirement clinical trial Smokers , quit time le 3 month , ca n't quit smoke trial . Use prescription drug within 4 week prior dose , overthecounter medication ( vitamin , herbal supplement , dietary supplement ) within 2 week prior dose , treat direct low gastrointestinal use steroid . Participation clinical investigation within 3 month prior dose Donation loss 400 mL blood within 8 week prior first dose Significant illness within 2 week prior dose , investigator judge n't fit participate trial . A history clinical significance abnormal ECG family history long QT syndrome ( grandparent , parent sibling ) Have family history diabetes ( grandparent , parent sibling ) . Have history acute chronic bronchial spasm ( include treatment treatment asthma chronic obstructive pulmonary disease ) Have history drug allergy atopic disease allergy ( asthma , urticaria , eczema , dermatitis ) , allergy history trail drug similar drug . Have gastrointestinal disease , history liver disease , gastrointestinal disease , gastrointestinal surgery ( appendix remove except ) chronic pancreatitis , history idiopathic acute pancreatitis , opinion investigator , clinical significant . Have personal family history medullary thyroid cancer ( MTC ) hereditary disease induce MTC . Have history immunodeficiency disease , include human immunodeficiency virus ( HIV ) antibody positive . Have history needlesickness , opinion investigator , clinical significant . Have unknown cause infection . In screening , abnormal result physical examination , vital sign , electrocardiogram ( ECG ) clinical laboratory , opinion investigator , clinical significant . Hepatitis b surface antigen hepatitis c antibody positive , treponema pallidum antibody positive . Abuse drug alcohol within 12 month first dose , screen find evidence abuse laboratory test . People pregnant , nursing mother , near future plan pregnant , show pregnancy test positive group . In screening , lie position ( 3 minute rest ) systolic blood pressure outside range 90 ~ 140 MMHG , diastolic blood pressure outside range 5090 MMHG , pulse ( HR ) outside range 40 ~ 100 bpm , boundary value group . Have chang weight &gt; 3 kg within 3 month selfreport . Subjects , opinion investigator , way unsuitable participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>GLP-1 receptor agonist</keyword>
</DOC>